Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults 65 Years of Age

  • STATUS
    Recruiting
  • End date
    Jun 18, 2021
  • participants needed
    1780
  • sponsor
    Pfizer
Updated on 16 December 2020
Investigator
Pfizer CT.gov Call Center
Primary Contact
Diablo Clinical Research, Inc. (4.7 mi away) Contact
+71 other location
pneumococcal conjugate
vaccination
trivalent influenza vaccine
conjugate vaccine
pneumococcal vaccine

Summary

Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately

Details
Treatment Saline, Influenza vaccine, Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Clinical Study IdentifierNCT04526574
SponsorPfizer
Last Modified on16 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet